July 19, 2021 09:51 AM EDT

AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer

Kyle Blankenship

One of the first entrants in the PD-(L)1 market in China, British drugmaker AstraZeneca is now looking to cement its advantage there with another approval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer

Kyle Blankenship

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

As­traZeneca earns an­oth­er ap­proval in jam-packed Chi­nese PD-(L)1 mar­ket, this time in late-stage lung can­cer

Kyle Blankenship

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus